Clopidogrel News and Research

RSS
Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Cardiologists question FDA recommendations on genetic testing before taking Plavix

Cardiologists question FDA recommendations on genetic testing before taking Plavix

STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

Ticagrelor drug may reduce risk of dying following heart attack

Ticagrelor drug may reduce risk of dying following heart attack

Coronary artery bypass graft surgery provides better health status, quality of life in diabetic patients

Coronary artery bypass graft surgery provides better health status, quality of life in diabetic patients

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Anti-thrombotic therapy interruption has no influence on perioperative complications in cardiac patients

Anti-thrombotic therapy interruption has no influence on perioperative complications in cardiac patients

Pre-treatment with prasugrel increases risk of bleeding without reducing risk of ischemic events

Pre-treatment with prasugrel increases risk of bleeding without reducing risk of ischemic events

Research: General practitioners undertreat women with atrial fibrillation

Research: General practitioners undertreat women with atrial fibrillation

Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Older heart patients present unique challenges for determining optimal dosages of medications

Older heart patients present unique challenges for determining optimal dosages of medications

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen receives complete response letter from FDA for XARELTO sNDA

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

Faster, more potent antithrombotic drugs recommended for high-risk heart attack patients

Faster, more potent antithrombotic drugs recommended for high-risk heart attack patients

New AAN guideline provides direction for use of blood thinners during surgery

New AAN guideline provides direction for use of blood thinners during surgery